S&P 500 Futures
(0.32%) 5 107.75 points
Dow Jones Futures
(0.69%) 38 647 points
Nasdaq Futures
(0.62%) 17 760 points
Oil
(0.30%) $79.19
Gas
(0.25%) $2.04
Gold
(0.02%) $2 310.10
Silver
(-0.13%) $26.80
Platinum
(1.44%) $976.50
USD/EUR
(-0.16%) $0.931
USD/NOK
(-0.46%) $10.94
USD/GBP
(-0.24%) $0.796
USD/RUB
(0.57%) $91.65

Aktualne aktualizacje dla Guardant Health Inc [GH]

Giełda: NASDAQ Sektor: Healthcare Branża: Diagnostics & Research
BUY
80.00%
return -0.76%
SELL
50.00%
return -4.18%
Ostatnio aktualizowano2 geg. 2024 @ 23:00

1.75% $ 18.58

KUPNO 113205 min ago

@ $22.28

Wydano: 14 vas. 2024 @ 20:20


Zwrot: -16.61%


Poprzedni sygnał: vas. 14 - 16:30


Poprzedni sygnał: Sprzedaż


Zwrot: 1.83 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients...

Stats
Dzisiejszy wolumen 926 814
Średni wolumen 1.94M
Kapitalizacja rynkowa 2.26B
EPS $0 ( 2024-02-22 )
Następna data zysków ( $-0.940 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.34
ATR14 $0.0170 (0.09%)
Insider Trading
Date Person Action Amount type
2024-04-30 Krognes Steve E. Sell 154 Restricted Stock Units
2024-04-30 Krognes Steve E. Buy 154 Common Stock
2024-04-15 Tariq Musa Sell 249 Restricted Stock Units
2024-04-15 Tariq Musa Buy 249 Common Stock
2024-04-15 Saia John G. Buy 7 569 Common Stock
INSIDER POWER
-46.47
Last 99 transactions
Buy: 862 724 | Sell: 2 348 187

Wolumen Korelacja

Długi: 0.01 (neutral)
Krótki: 0.54 (weak)
Signal:(50.752) Neutral

Guardant Health Inc Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Guardant Health Inc Korelacja - Waluta/Towar

The country flag -0.08
( neutral )
The country flag 0.28
( neutral )
The country flag 0.00
( neutral )
The country flag -0.21
( neutral )
The country flag 0.82
( strong )
The country flag 0.19
( neutral )

Guardant Health Inc Finanse

Annual 2023
Przychody: $563.95M
Zysk brutto: $336.90M (59.74 %)
EPS: $-4.28
FY 2023
Przychody: $563.95M
Zysk brutto: $336.90M (59.74 %)
EPS: $-4.28
FY 2022
Przychody: $449.54M
Zysk brutto: $293.21M (65.23 %)
EPS: $-6.41
FY 2021
Przychody: $373.65M
Zysk brutto: $250.74M (67.11 %)
EPS: $-4.00

Financial Reports:

No articles found.

Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej